To the best of our knowledge, there are no studies on BRAF-mutated melanoma cells where the PIK3CA mutation was artificially induced and concomitantly treated with BRAF/PI3K or MEK/PI3K inhibitors. This evidence concerns the gene MAP2K7 and melanoma.